Industry

AstraZeneca invests $2 billion in Summit to test cancer drug combinations

AstraZeneca will invest $2 billion in Summit and jointly fund trials pairing ivonescimab with its cancer drug sone-ve.

Reported by 3 outlets Wednesday, September 30, 2026

Cancer cells under a fluorescence microscope
Photo: CC0

AstraZeneca will invest $2 billion in Summit Therapeutics and work with the company to test cancer drug combinations, according to reports. The partners will initially study Summit’s ivonescimab with AstraZeneca’s antibody-drug conjugate sonesitatug vedotin, also called sone-ve, in gastrointestinal cancers.

The companies will jointly fund the clinical trials and retain development and commercial rights to their respective drugs, according to the reports. They also signed a nonbinding agreement to consider testing ivonescimab with other AstraZeneca cancer medicines, including other antibody-drug conjugates. The initial trials are expected to be sponsored by AstraZeneca, MedCity News reported.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.